ECM
ATNM icon

ETrade Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

ETrade Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,673
Closed -$28K – 886
2020
Q2 		$28K Buy
+2,673
New +$20.2K ﹤0.01% 830

Other funds holding ATNM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ETrade Capital Management's ATNM Position: Q3 2020 in Review

ETrade Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 2,673 shares — an estimated $28K sold.

ETrade Capital Management first reported a position in ATNM in Q2 2020 and held it in 1 quarter. The position peaked at $28K in Q2 2020. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

  • ETrade Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • ETrade Capital Management sold 2,673 Actinium Pharmaceuticals shares in Q3 2020, an estimated $28K.
  • ETrade Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • ETrade Capital Management's Actinium Pharmaceuticals position peaked at $28K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.